{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:22:50Z","timestamp":1775161370599,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2000,12]]},"DOI":"10.1053\/sarh.2000.16641","type":"journal-article","created":{"date-parts":[[2002,10,9]],"date-time":"2002-10-09T20:53:46Z","timestamp":1034196826000},"page":"196-208","source":"Crossref","is-referenced-by-count":65,"title":["Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis"],"prefix":"10.1053","volume":"30","author":[{"given":"Michael H.","family":"Schiff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Whelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/sarh.2000.16641_NEWBIB1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.1780351003","article-title":"Use of short-term efficacy\/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis","volume":"35","author":"Felson","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB2","first-page":"1885","article-title":"Longterm therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone","volume":"19","author":"Pincus","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB3","first-page":"228","article-title":"Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to non-steroidal anti-inflammatory drugs","volume":"15","author":"Kleinknecht","year":"1995","journal-title":"Semin Nephrol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann NY Acad Sci"},{"key":"10.1053\/sarh.2000.16641_NEWBIB5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/art.1780300102","article-title":"Cyclosporin A treatment of refractory rheumatoid arthritis","volume":"30","author":"Weinblatt","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/BF00606627","article-title":"Effects of cyclosporin on serum creatinine in patients with rheumatoid arthritis","volume":"31","author":"Dijkmans","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.7326\/0003-4819-109-11-863","article-title":"Cyclosporin A in severe, treatment-refractory rheumatoid arthritis","volume":"109","author":"Yocum","year":"1988","journal-title":"Ann Intern Med"},{"issue":"suppl A","key":"10.1053\/sarh.2000.16641_NEWBIB8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0896-8411(92)90053-S","article-title":"The effect of cyclosporin on renal function","volume":"5","author":"Mason","year":"1992","journal-title":"J Autoimmun"},{"issue":"suppl 1","key":"10.1053\/sarh.2000.16641_NEWBIB9","first-page":"65","volume":"32","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB10","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1056\/NEJM199206183262502","article-title":"Risk factor for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases","volume":"326","author":"Feutren","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB11","first-page":"33","article-title":"Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis","volume":"41","author":"Sund","year":"1994","journal-title":"Clin Nephrol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.1780390908","article-title":"Renal biopsy findings and follow-up of renal function in rheumatoid arthritis patients treated with cyclosporin A: an update form the International Kidney Biopsy Registry","volume":"39","author":"Rodriguez","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB13","first-page":"61","article-title":"Longterm, low dose cyclosporine in patients with rheumatoid arthritis: renal function loss without structural nephropathy","volume":"23","author":"Landewe","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.47.2.127","article-title":"Cyclosporin in rheumatoid arthritis: a double blind, placebo-controlled study in 52 patients","volume":"47","author":"Dougados","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/sarh.2000.16641_NEWBIB15","first-page":"1485","article-title":"A study of the long-term efficacy and toxicity of cyclosporin A in rheumatoid arthritis","volume":"18","author":"Madhok","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB16","first-page":"1631","article-title":"Cyclosporin in common clinical practice: an estimation of the benefit\/risk ratio in patients with rheumatoid arthritis","volume":"21","author":"Landewe","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/art.1780371015","article-title":"Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: results of a 48-week multicenter study comparing low-dose cyclosporine and placebo","volume":"37","author":"Forre","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/0002-9343(92)90169-C","article-title":"Interaction of cyclosporine A and non-steroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis","volume":"93","author":"Altman","year":"1992","journal-title":"Am J Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB19","first-page":"1176","article-title":"US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis","volume":"26","author":"Cush","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2165\/00002512-199507060-00003","article-title":"Disease-modifying antirheumatic drugs: potential effects in older patients","volume":"7","author":"Gardner","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1053\/sarh.2000.16641_NEWBIB21","first-page":"S39","article-title":"Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis","volume":"16","author":"Raman","year":"1998","journal-title":"J Hypertens"},{"key":"10.1053\/sarh.2000.16641_NEWBIB22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(99)08421-4","article-title":"Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial","volume":"354","author":"Rahn","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/sarh.2000.16641_NEWBIB23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000185185","article-title":"Gold nephropathy","volume":"50","author":"Hall","year":"1988","journal-title":"Nephron"},{"key":"10.1053\/sarh.2000.16641_NEWBIB24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/bmj.295.6601.745","article-title":"The natural course of gold nephropathy: a long-term study of 21 patients","volume":"295","author":"Hall","year":"1987","journal-title":"Br Med J"},{"key":"10.1053\/sarh.2000.16641_NEWBIB25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-1-4684-8953-8_23","article-title":"The natural course of gold and penicillamine nephropathy: a longterm study of 54 patients","volume":"252","author":"Hall","year":"1989","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00005792-197807000-00003","article-title":"Membranous nephropathy in patients with rheumatoid arthritis: relationship to gold therapy","volume":"57","author":"Samuels","year":"1977","journal-title":"Medicine"},{"key":"10.1053\/sarh.2000.16641_NEWBIB27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000183671","article-title":"Mild mesangial glomerulopathy: a frequent finding in patients with hematuria or proteinuria","volume":"42","author":"Helin","year":"1986","journal-title":"Nephron"},{"key":"10.1053\/sarh.2000.16641_NEWBIB28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/art.1780220509","article-title":"Long term chrysotherapy","volume":"22","author":"Kean","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB29","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/00007611-197912000-00041","article-title":"Renal vein thrombosis associated with nephrotic syndrome and gold therapy in rheumatoid arthritis","volume":"72","author":"Nelson","year":"1979","journal-title":"South Med J"},{"key":"10.1053\/sarh.2000.16641_NEWBIB30","first-page":"50","article-title":"Gold nephropathy in juvenile rheumatoid arthritis","volume":"133","author":"Husserl","year":"1979","journal-title":"Am J Dis Child"},{"key":"10.1053\/sarh.2000.16641_NEWBIB31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/ard.35.6.477","article-title":"Selective concentration and localization of gold in macrophages of synovial and other tissues during and after chrysotherapy in rheumatoid patients","volume":"35","author":"Vernon-Roberts","year":"1976","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/sarh.2000.16641_NEWBIB32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/31.1.53","article-title":"Complement C4 null alleles as a marker of gold or D-penicillamine toxicity in the treatment of rheumatoid arthritis","volume":"31","author":"Clarkson","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB33","first-page":"167","article-title":"Auranofin therapy in rheumatoid arthritis","volume":"100","author":"Bernhard","year":"1982","journal-title":"J Lab Clin Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF02229867","article-title":"Randomized trial of switching rheumatoid arthritis patients in remission with injectable gold to auranofin","volume":"13","author":"Prete","year":"1994","journal-title":"Clin Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.7326\/0003-4819-92-1-24","article-title":"Adverse effects of D-penicillamine in rheumatoid arthritis","volume":"92","author":"Stein","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0002-9343(78)90186-9","article-title":"Toxicity of D-penicillamine in rheumatoid arthritis: a report of 63 patients including two with aplastic anemia and one with nephrotic syndrome","volume":"64","author":"Weiss","year":"1978","journal-title":"Am J Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/art.1780230205","article-title":"The toxicity pattern of D-penicillamine therapy: a guide to its use in rheumatoid arthritis","volume":"23","author":"Kean","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0049-0172(86)90023-5","article-title":"Penicillamine-induced proteinuria: risk factors","volume":"15","author":"Stein","year":"1986","journal-title":"Semin Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/03009748209098183","article-title":"Low-dose penicillamine treatment of RA: comparison of 300 mg and 600 mg regimens","volume":"11","author":"Nissila","year":"1982","journal-title":"Scand J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1532-5415.1982.tb01281.x","article-title":"Efficacy and toxicity of D-penicillamine for rheumatoid disease in the elderly","volume":"30","author":"Kean","year":"1982","journal-title":"J Amer Geriatr Soc"},{"key":"10.1053\/sarh.2000.16641_NEWBIB41","first-page":"661","article-title":"Penicillamine nephropathy in rheumatoid arthritis: a clinical, pathological, and immunological study","volume":"45","author":"Bacon","year":"1976","journal-title":"QJM"},{"key":"10.1053\/sarh.2000.16641_NEWBIB42","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/bmj.296.6629.1083","article-title":"Natural course of penicillamine nephropathy: a long term study of 33 patients","volume":"296","author":"Hall","year":"1988","journal-title":"Br Med J"},{"key":"10.1053\/sarh.2000.16641_NEWBIB43","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1136\/bmj.280.6230.1498","article-title":"Adverse reactions to D-penicillamine after gold toxicity","volume":"21","author":"Dodd","year":"1980","journal-title":"Br Med J"},{"issue":"suppl 3","key":"10.1053\/sarh.2000.16641_NEWBIB44","first-page":"109","article-title":"Effect of penicillamine on the kidney","volume":"70","author":"Davison","year":"1977","journal-title":"Proc R Soc Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780260502","article-title":"Low-dose D-penicillamine therapy in rheumatoid arthritis","volume":"26","author":"Williams","year":"1983","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB46","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB47","first-page":"S212","article-title":"Renal effects of leflunomide compared with other agents used to treat rheumatoid arthritis (RA)","author":"Scott","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/sarh.2000.16641_NEWBIB48","first-page":"38","article-title":"Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy","volume":"22","author":"Kremer","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB49","first-page":"1126","article-title":"Renal effects of low dose methotrexate in rheumatoid arthritis","volume":"20","author":"Seideman","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB50","first-page":"973","article-title":"The effect of age on methotrexate efficacy and toxicity","volume":"18","author":"Wolfe","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB51","first-page":"218","article-title":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis","volume":"22","author":"Rheumatoid Arthritis Clinical Trial Archive Group","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB52","series-title":"Physicians' Desk Reference","first-page":"1424","year":"2000"},{"issue":"suppl 1","key":"10.1053\/sarh.2000.16641_NEWBIB53","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/ard.41.Suppl_1.44","article-title":"Rheumatoid arthritis: treatment with azathioprine (Imuran): clinical side effects and laboratory abnormalities","volume":"41","author":"Whisnant","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/sarh.2000.16641_NEWBIB54","first-page":"697","article-title":"Toxic effects of azathioprine in rheumatoid arthritis","volume":"26","author":"Singh","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0002-9343(83)91269-X","article-title":"Dose refinement in long-term therapy of rheumatoid arthritis with antimalarials","volume":"75","author":"McKenzie","year":"1983","journal-title":"Am J Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB56","first-page":"34","article-title":"Antimalarial drug-induced decrease in creatinine clearance","volume":"22","author":"Landewe","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB57","first-page":"1672","article-title":"Sulfasalazine in early rheumatoid arthritis","volume":"19","author":"The Australian Multicentre Trial Group","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB58","first-page":"195","article-title":"Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5-year follow-up","volume":"18","author":"Jones","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB59","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bi952168g","article-title":"The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase","volume":"35","author":"Davis","year":"1996","journal-title":"Biochemistry"},{"issue":"suppl 53","key":"10.1053\/sarh.2000.16641_NEWBIB60","first-page":"20","article-title":"Mechanism of action of leflunomide in rheumatoid arthritis","volume":"25","author":"Fox","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB61","doi-asserted-by":"crossref","first-page":"29682","DOI":"10.1074\/jbc.270.50.29682","article-title":"Importance of ribonucleotide availability to proliferating T lymphocytes from healthy humans: disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors","volume":"270","author":"Fairbanks","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1053\/sarh.2000.16641_NEWBIB62","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/sarh.2000.16641_NEWBIB63","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/rheumatology\/31.5.293","article-title":"TNF-\u03b1 a pivotal role in rheumatoid arthritis?","volume":"31","author":"Brennan","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB64","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB65","first-page":"S401","article-title":"Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis","volume":"42","author":"Moreland","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB66","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB67","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB68","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.1780390502","article-title":"Guidelines for the management of rheumatoid arthritis","volume":"39","author":"American College of Rheumatology Ad Hoc Committee","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1053\/sarh.2000.16641_NEWBIB69","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0002-9343(99)00113-8","article-title":"Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications","volume":"106","author":"Whelton","year":"1999","journal-title":"Am J Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00002512-199609050-00005","article-title":"Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly: a risk-benefit assessment","volume":"9","author":"Ailabouni","year":"1996","journal-title":"Drugs Aging"},{"key":"10.1053\/sarh.2000.16641_NEWBIB71","first-page":"90","article-title":"Renal papillary necrosis due to naproxen","volume":"11","author":"Caruana","year":"1984","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB72","first-page":"994","article-title":"Termination of slow-acting antirheumatic therapy in rheumatoid arthritis","volume":"17","author":"Wolfe","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1053\/sarh.2000.16641_NEWBIB73","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O'Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM199507203330301","article-title":"Combination therapy with cyclosporin and methotrexate in severe rheumatoid arthritis","volume":"333","author":"Tugwell","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/sarh.2000.16641_NEWBIB75","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/1529-0131(199907)42:7<1322::AID-ANR4>3.0.CO;2-P","article-title":"Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis","volume":"42","author":"Weinblatt","year":"1999","journal-title":"Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017200394811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017200394811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T10:51:17Z","timestamp":1554720677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017200394811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["S0049017200394811"],"URL":"https:\/\/doi.org\/10.1053\/sarh.2000.16641","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}